Long-term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan

C. C. Lin, Jaw Ching Wu, Ting-Tsung Chang, Y. H. Huang, Y. J. Wang, S. H. Tsay, Nan-Haw Chow, F. Y. Chang, S. D. Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The effect of interferon (IFN) on hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) has not been fully investigated in Chinese patients. We enrolled 58 HBeAg-negative CHB Chinese patients with hepatitis B viremia in Taiwan to evaluate the response to IFN. 30 patients received recombinant IFN 5 million units 3 times weekly for 6-10 months, and 28 patients who refused IFN treatment served as controls. Rates of virological response and biochemical response were higher in the treated group at the end of treatment (57% vs 18%, P = 0.006, and 73% vs 29%, P = 0.002, respectively). Both effects were superior in the treated group at 6 months after IFN withdrawal (virological: 30% vs 7%, P = 0.06; biochemical: 47% vs 7%, P = 0.002). Improvement of liver histological activities with persistently biochemical response was found in 65% of the treated patients. After a mean of 32 months' follow-up, virological response was rarely maintained (17% vs 4%, P = 0.228) but biochemical response was better in the treated group (27% vs 4%, P = 0.039). None of the treated patients but five controls developed severe complications of CHB during the follow-up period. A larger total IFN dosage or a younger age (≤ 40 years) were associated with 'sustained' virological response. Younger age and higher baseline alanine transaminase values (≥ 120 Ul-1) were related to 'sustained' biochemical response.

Original languageEnglish
Pages (from-to)438-446
Number of pages9
JournalJournal of Viral Hepatitis
Volume8
Issue number6
DOIs
Publication statusPublished - 2001 Jan 1

Fingerprint

Hepatitis B e Antigens
Chronic Hepatitis B
Taiwan
Interferons
Therapeutics
Viremia
Hepatitis B
Alanine Transaminase
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases
  • Virology

Cite this

Lin, C. C. ; Wu, Jaw Ching ; Chang, Ting-Tsung ; Huang, Y. H. ; Wang, Y. J. ; Tsay, S. H. ; Chow, Nan-Haw ; Chang, F. Y. ; Lee, S. D. / Long-term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. In: Journal of Viral Hepatitis. 2001 ; Vol. 8, No. 6. pp. 438-446.
@article{f00f4c6d6a1a4213bbc29c8caa47b45b,
title = "Long-term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan",
abstract = "The effect of interferon (IFN) on hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) has not been fully investigated in Chinese patients. We enrolled 58 HBeAg-negative CHB Chinese patients with hepatitis B viremia in Taiwan to evaluate the response to IFN. 30 patients received recombinant IFN 5 million units 3 times weekly for 6-10 months, and 28 patients who refused IFN treatment served as controls. Rates of virological response and biochemical response were higher in the treated group at the end of treatment (57{\%} vs 18{\%}, P = 0.006, and 73{\%} vs 29{\%}, P = 0.002, respectively). Both effects were superior in the treated group at 6 months after IFN withdrawal (virological: 30{\%} vs 7{\%}, P = 0.06; biochemical: 47{\%} vs 7{\%}, P = 0.002). Improvement of liver histological activities with persistently biochemical response was found in 65{\%} of the treated patients. After a mean of 32 months' follow-up, virological response was rarely maintained (17{\%} vs 4{\%}, P = 0.228) but biochemical response was better in the treated group (27{\%} vs 4{\%}, P = 0.039). None of the treated patients but five controls developed severe complications of CHB during the follow-up period. A larger total IFN dosage or a younger age (≤ 40 years) were associated with 'sustained' virological response. Younger age and higher baseline alanine transaminase values (≥ 120 Ul-1) were related to 'sustained' biochemical response.",
author = "Lin, {C. C.} and Wu, {Jaw Ching} and Ting-Tsung Chang and Huang, {Y. H.} and Wang, {Y. J.} and Tsay, {S. H.} and Nan-Haw Chow and Chang, {F. Y.} and Lee, {S. D.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1046/j.1365-2893.2001.00320.x",
language = "English",
volume = "8",
pages = "438--446",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "6",

}

Long-term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. / Lin, C. C.; Wu, Jaw Ching; Chang, Ting-Tsung; Huang, Y. H.; Wang, Y. J.; Tsay, S. H.; Chow, Nan-Haw; Chang, F. Y.; Lee, S. D.

In: Journal of Viral Hepatitis, Vol. 8, No. 6, 01.01.2001, p. 438-446.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term evaluation of recombinant interferon α2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan

AU - Lin, C. C.

AU - Wu, Jaw Ching

AU - Chang, Ting-Tsung

AU - Huang, Y. H.

AU - Wang, Y. J.

AU - Tsay, S. H.

AU - Chow, Nan-Haw

AU - Chang, F. Y.

AU - Lee, S. D.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - The effect of interferon (IFN) on hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) has not been fully investigated in Chinese patients. We enrolled 58 HBeAg-negative CHB Chinese patients with hepatitis B viremia in Taiwan to evaluate the response to IFN. 30 patients received recombinant IFN 5 million units 3 times weekly for 6-10 months, and 28 patients who refused IFN treatment served as controls. Rates of virological response and biochemical response were higher in the treated group at the end of treatment (57% vs 18%, P = 0.006, and 73% vs 29%, P = 0.002, respectively). Both effects were superior in the treated group at 6 months after IFN withdrawal (virological: 30% vs 7%, P = 0.06; biochemical: 47% vs 7%, P = 0.002). Improvement of liver histological activities with persistently biochemical response was found in 65% of the treated patients. After a mean of 32 months' follow-up, virological response was rarely maintained (17% vs 4%, P = 0.228) but biochemical response was better in the treated group (27% vs 4%, P = 0.039). None of the treated patients but five controls developed severe complications of CHB during the follow-up period. A larger total IFN dosage or a younger age (≤ 40 years) were associated with 'sustained' virological response. Younger age and higher baseline alanine transaminase values (≥ 120 Ul-1) were related to 'sustained' biochemical response.

AB - The effect of interferon (IFN) on hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) has not been fully investigated in Chinese patients. We enrolled 58 HBeAg-negative CHB Chinese patients with hepatitis B viremia in Taiwan to evaluate the response to IFN. 30 patients received recombinant IFN 5 million units 3 times weekly for 6-10 months, and 28 patients who refused IFN treatment served as controls. Rates of virological response and biochemical response were higher in the treated group at the end of treatment (57% vs 18%, P = 0.006, and 73% vs 29%, P = 0.002, respectively). Both effects were superior in the treated group at 6 months after IFN withdrawal (virological: 30% vs 7%, P = 0.06; biochemical: 47% vs 7%, P = 0.002). Improvement of liver histological activities with persistently biochemical response was found in 65% of the treated patients. After a mean of 32 months' follow-up, virological response was rarely maintained (17% vs 4%, P = 0.228) but biochemical response was better in the treated group (27% vs 4%, P = 0.039). None of the treated patients but five controls developed severe complications of CHB during the follow-up period. A larger total IFN dosage or a younger age (≤ 40 years) were associated with 'sustained' virological response. Younger age and higher baseline alanine transaminase values (≥ 120 Ul-1) were related to 'sustained' biochemical response.

UR - http://www.scopus.com/inward/record.url?scp=0035552878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035552878&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2893.2001.00320.x

DO - 10.1046/j.1365-2893.2001.00320.x

M3 - Article

VL - 8

SP - 438

EP - 446

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 6

ER -